Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

Mark Hyman Rapaport, Georges M. Gharabawi, Carla M. Canuso, Ramy A. Mahmoud, Martin B. Keller, Cynthia A. Bossie, Ibrahim Turkoz, Robert A. Lasser, Amy Loescher, Philippe Bouhours, Fiona Dunbar, Charles Nemeroff

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Approximately one-third of persons with depression do not respond to antidepressant monotherapy. Studies suggest that atypical antipsychotic augmentation may benefit these patients. We investigated the longer-term efficacy of risperidone augmentation of serotonin-selective reuptake inhibitor treatment for resistant depression. In 57 in- and outpatient centers in three countries, we conducted a three-phase study with 4-6 weeks of open-label citalopram monotherapy, 4-6 weeks of open-label risperidone augmentation, and a 24-week double-blind, placebo-controlled discontinuation phase. A total of 489 patients with major depressive disorder and 1-3 documented treatment failures entered the citalopram monotherapy phase (20-60 mg/day). Patients with <50% reduction in HAM-D-17 scores entered the risperidone augmentation phase (0.25-2.0 mg/day). Patients with HAM-D-17≤7 or CGI-S≤2 were randomized to risperidone or placebo augmentation. The primary outcome was time to relapse during the double-blind phase. During citalopram monotherapy, 434 patients had <50% HAM-D-17 reduction; 299 (68.9%) were fully nonresponsive (<25% reduction) and 135 were partially nonresponsive (25-49% reduction). Of the 386 nonresponders who entered the augmentation phase, 243 remitted and 241 entered the double-blind phase. Median time to relapse was 102 days with risperidone augmentation and 85 days with placebo (NS); relapse rates were 53.3 and 54.6%, respectively. In a post hoc analysis of patients fully nonresponsive to citalopram monotherapy, median time to relapse was 97 days with risperidone augmentation and 56 with placebo (p=0.05); relapse rates were 56.1 and 64.1%, respectively (p≤0.05). Open-label risperidone augmentation substantially enhanced response in treatment-resistant patients, but the longer-term benefits of augmentation were not demonstrated in this study.

Original languageEnglish
Pages (from-to)2505-2513
Number of pages9
JournalNeuropsychopharmacology
Volume31
Issue number11
DOIs
StatePublished - Nov 7 2006
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Risperidone
Citalopram
Recurrence
Placebos
Therapeutics
Serotonin Uptake Inhibitors
Treatment Failure
Antidepressive Agents
Antipsychotic Agents
Inpatients
Outpatients
Depression

Keywords

  • Citalopram
  • Resistant depression
  • Risperidone augmentation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of risperidone augmentation in patients with treatment-resistant depression : Results of open-label treatment followed by double-blind continuation. / Rapaport, Mark Hyman; Gharabawi, Georges M.; Canuso, Carla M.; Mahmoud, Ramy A.; Keller, Martin B.; Bossie, Cynthia A.; Turkoz, Ibrahim; Lasser, Robert A.; Loescher, Amy; Bouhours, Philippe; Dunbar, Fiona; Nemeroff, Charles.

In: Neuropsychopharmacology, Vol. 31, No. 11, 07.11.2006, p. 2505-2513.

Research output: Contribution to journalArticle

Rapaport, MH, Gharabawi, GM, Canuso, CM, Mahmoud, RA, Keller, MB, Bossie, CA, Turkoz, I, Lasser, RA, Loescher, A, Bouhours, P, Dunbar, F & Nemeroff, C 2006, 'Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation', Neuropsychopharmacology, vol. 31, no. 11, pp. 2505-2513. https://doi.org/10.1038/sj.npp.1301113
Rapaport, Mark Hyman ; Gharabawi, Georges M. ; Canuso, Carla M. ; Mahmoud, Ramy A. ; Keller, Martin B. ; Bossie, Cynthia A. ; Turkoz, Ibrahim ; Lasser, Robert A. ; Loescher, Amy ; Bouhours, Philippe ; Dunbar, Fiona ; Nemeroff, Charles. / Effects of risperidone augmentation in patients with treatment-resistant depression : Results of open-label treatment followed by double-blind continuation. In: Neuropsychopharmacology. 2006 ; Vol. 31, No. 11. pp. 2505-2513.
@article{fde6f673bea349b9b3844343f22cf0d8,
title = "Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation",
abstract = "Approximately one-third of persons with depression do not respond to antidepressant monotherapy. Studies suggest that atypical antipsychotic augmentation may benefit these patients. We investigated the longer-term efficacy of risperidone augmentation of serotonin-selective reuptake inhibitor treatment for resistant depression. In 57 in- and outpatient centers in three countries, we conducted a three-phase study with 4-6 weeks of open-label citalopram monotherapy, 4-6 weeks of open-label risperidone augmentation, and a 24-week double-blind, placebo-controlled discontinuation phase. A total of 489 patients with major depressive disorder and 1-3 documented treatment failures entered the citalopram monotherapy phase (20-60 mg/day). Patients with <50{\%} reduction in HAM-D-17 scores entered the risperidone augmentation phase (0.25-2.0 mg/day). Patients with HAM-D-17≤7 or CGI-S≤2 were randomized to risperidone or placebo augmentation. The primary outcome was time to relapse during the double-blind phase. During citalopram monotherapy, 434 patients had <50{\%} HAM-D-17 reduction; 299 (68.9{\%}) were fully nonresponsive (<25{\%} reduction) and 135 were partially nonresponsive (25-49{\%} reduction). Of the 386 nonresponders who entered the augmentation phase, 243 remitted and 241 entered the double-blind phase. Median time to relapse was 102 days with risperidone augmentation and 85 days with placebo (NS); relapse rates were 53.3 and 54.6{\%}, respectively. In a post hoc analysis of patients fully nonresponsive to citalopram monotherapy, median time to relapse was 97 days with risperidone augmentation and 56 with placebo (p=0.05); relapse rates were 56.1 and 64.1{\%}, respectively (p≤0.05). Open-label risperidone augmentation substantially enhanced response in treatment-resistant patients, but the longer-term benefits of augmentation were not demonstrated in this study.",
keywords = "Citalopram, Resistant depression, Risperidone augmentation",
author = "Rapaport, {Mark Hyman} and Gharabawi, {Georges M.} and Canuso, {Carla M.} and Mahmoud, {Ramy A.} and Keller, {Martin B.} and Bossie, {Cynthia A.} and Ibrahim Turkoz and Lasser, {Robert A.} and Amy Loescher and Philippe Bouhours and Fiona Dunbar and Charles Nemeroff",
year = "2006",
month = "11",
day = "7",
doi = "10.1038/sj.npp.1301113",
language = "English",
volume = "31",
pages = "2505--2513",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Effects of risperidone augmentation in patients with treatment-resistant depression

T2 - Results of open-label treatment followed by double-blind continuation

AU - Rapaport, Mark Hyman

AU - Gharabawi, Georges M.

AU - Canuso, Carla M.

AU - Mahmoud, Ramy A.

AU - Keller, Martin B.

AU - Bossie, Cynthia A.

AU - Turkoz, Ibrahim

AU - Lasser, Robert A.

AU - Loescher, Amy

AU - Bouhours, Philippe

AU - Dunbar, Fiona

AU - Nemeroff, Charles

PY - 2006/11/7

Y1 - 2006/11/7

N2 - Approximately one-third of persons with depression do not respond to antidepressant monotherapy. Studies suggest that atypical antipsychotic augmentation may benefit these patients. We investigated the longer-term efficacy of risperidone augmentation of serotonin-selective reuptake inhibitor treatment for resistant depression. In 57 in- and outpatient centers in three countries, we conducted a three-phase study with 4-6 weeks of open-label citalopram monotherapy, 4-6 weeks of open-label risperidone augmentation, and a 24-week double-blind, placebo-controlled discontinuation phase. A total of 489 patients with major depressive disorder and 1-3 documented treatment failures entered the citalopram monotherapy phase (20-60 mg/day). Patients with <50% reduction in HAM-D-17 scores entered the risperidone augmentation phase (0.25-2.0 mg/day). Patients with HAM-D-17≤7 or CGI-S≤2 were randomized to risperidone or placebo augmentation. The primary outcome was time to relapse during the double-blind phase. During citalopram monotherapy, 434 patients had <50% HAM-D-17 reduction; 299 (68.9%) were fully nonresponsive (<25% reduction) and 135 were partially nonresponsive (25-49% reduction). Of the 386 nonresponders who entered the augmentation phase, 243 remitted and 241 entered the double-blind phase. Median time to relapse was 102 days with risperidone augmentation and 85 days with placebo (NS); relapse rates were 53.3 and 54.6%, respectively. In a post hoc analysis of patients fully nonresponsive to citalopram monotherapy, median time to relapse was 97 days with risperidone augmentation and 56 with placebo (p=0.05); relapse rates were 56.1 and 64.1%, respectively (p≤0.05). Open-label risperidone augmentation substantially enhanced response in treatment-resistant patients, but the longer-term benefits of augmentation were not demonstrated in this study.

AB - Approximately one-third of persons with depression do not respond to antidepressant monotherapy. Studies suggest that atypical antipsychotic augmentation may benefit these patients. We investigated the longer-term efficacy of risperidone augmentation of serotonin-selective reuptake inhibitor treatment for resistant depression. In 57 in- and outpatient centers in three countries, we conducted a three-phase study with 4-6 weeks of open-label citalopram monotherapy, 4-6 weeks of open-label risperidone augmentation, and a 24-week double-blind, placebo-controlled discontinuation phase. A total of 489 patients with major depressive disorder and 1-3 documented treatment failures entered the citalopram monotherapy phase (20-60 mg/day). Patients with <50% reduction in HAM-D-17 scores entered the risperidone augmentation phase (0.25-2.0 mg/day). Patients with HAM-D-17≤7 or CGI-S≤2 were randomized to risperidone or placebo augmentation. The primary outcome was time to relapse during the double-blind phase. During citalopram monotherapy, 434 patients had <50% HAM-D-17 reduction; 299 (68.9%) were fully nonresponsive (<25% reduction) and 135 were partially nonresponsive (25-49% reduction). Of the 386 nonresponders who entered the augmentation phase, 243 remitted and 241 entered the double-blind phase. Median time to relapse was 102 days with risperidone augmentation and 85 days with placebo (NS); relapse rates were 53.3 and 54.6%, respectively. In a post hoc analysis of patients fully nonresponsive to citalopram monotherapy, median time to relapse was 97 days with risperidone augmentation and 56 with placebo (p=0.05); relapse rates were 56.1 and 64.1%, respectively (p≤0.05). Open-label risperidone augmentation substantially enhanced response in treatment-resistant patients, but the longer-term benefits of augmentation were not demonstrated in this study.

KW - Citalopram

KW - Resistant depression

KW - Risperidone augmentation

UR - http://www.scopus.com/inward/record.url?scp=33750212103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750212103&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1301113

DO - 10.1038/sj.npp.1301113

M3 - Article

C2 - 16760927

AN - SCOPUS:33750212103

VL - 31

SP - 2505

EP - 2513

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 11

ER -